EPKINLY® for 3L+ DLBCL and FL EPKINLY® (epcoritamab-bysp) is a bispecific antibody given by subcutaneous injection for adults with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information Medication Guide, and Boxed Warnings
What is EPKINLY®? Treatment for 3L+ DLBCL and FL What is EPKINLY? EPKINLY is a treatment for certain types of B-cell lymphomas, which are a type of blood cancer EPKINLY is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) that returned or didn't respond after receiving 2 or more treatments EPKINLY is approved based on patient response data Studies are ongoing to confirm the clinical benefit of
DLBCL and FL Support and Resources - EPKINLY® (epcoritamab-bysp) Find patient and care partner support and resources for treatment with EPKINLY® (epcoritamab -bysp) of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information and Medication Guide, and Boxed Warnings
Starting on EPKINLY® (epcoritamab-bysp) Starting on EPKINLY EPKINLY is an injection; it is not an infusion, chemotherapy, or stem cell therapy EPKINLY is a treatment you can start as soon as you and your doctor are ready
EPKINLY® for 3L+ Diffuse Large B-Cell Lymphoma (DLBCL) EPKINLY® (epcoritamab-bysp) is a bispecific antibody given by subcutaneous injection for adults with certain types of diffuse large B-cell lymphoma (DLBCL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information Medication Guide, and Boxed Warnings
Clinical Trial Results - EPKINLY® (epcoritamab-bysp) View EPKINLY® (epcoritamab-bysp) clinical trial results for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information and Medication Guide, and Boxed Warnings
DLBCL Clinical Trial Results - EPKINLY® (epcoritamab-bysp) View EPKINLY® (epcoritamab-bysp) clinical trial results for certain types of diffuse large B-cell lymphoma (DLBCL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information Medication Guide, and Boxed Warnings
EPKINLY® for 3L+ Follicular Lymphoma (FL) EPKINLY® (epcoritimab-bysp) is a bispecific antibody given by subcutaneous injection for adults with follicular lymphoma (FL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information Medication Guide, and Boxed Warnings
DLBCL Patient Support and Resources - EPKINLY® (epcoritamab-bysp) Find patient support and resources for treatment with EPKINLY® (epcoritamab-bysp) for certain types of diffuse large B-cell lymphoma (DLBCL) that returned or didn't respond after 2 or more prior treatments See Important Safety Information, full Prescribing Information Medication Guide, and Boxed Warnings
What to Expect with EPKINLY EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large